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Abstract Antidepressant effects of mirtazapine and
imipramine were compared in a randomized, double
blind, fixed blood-level study with in-patients in a sin-
gle centre. Patients with a DSM-III-R diagnosis of
major depression and a Hamilton (17-item) score of
≥ 18 were selected. After a drug-free and a placebo-
washout period of 7 days in total, 107 patients still
fulfilling the HRSD criterion of ≥ 18, started on active
treatment. The dose was adjusted to a predefined fixed
blood level to avoid suboptimal dosing of imipramine.
Concomitant psychotropic medication was adminis-
tered only in a few cases because of intolerable anxi-
ety or intolerable psychotic symptoms. Eight patients
dropped out and two were excluded from analyses
because of non-compliance; 97 completed the study.
According to the main response criterion (50% or more
reduction on the HRSD score) 11/51 (21.6%) patients
responded on mirtazapine and 23/46 (50%) on
imipramine after 4 weeks’ treatment on the predefined
blood level. Such a dramatic difference in efficacy
between antidepressants has not often been reported
before. The selection of (severely ill) in-patients, includ-
ing those with suicidal or psychotic features, may have
significance in this respect. Optimization of treatment
with the reference drug imipramine through blood level
control, exclusion of non-compliance for both drugs,
exclusion of most concomitant medication and a low
drop-out rate may also have contributed. It is con-
cluded that imipramine is superior to mirtazapine in
the patient population studied.
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Introduction
Mirtazapine, a new piperazinoazepine, is a strong
antagonist of central a2-adrenoreceptors, H1(hista-
mine)-receptors, 5HT2-receptors (de Boer et al. 1988)
and 5HT3-receptors (Kooyman et al. 1994) and a
weaker antagonist of muscarine and a1-adrenorecep-
tors (de Boer et al. 1988). Mirtazapine has recently
been registered as an antidepressant. Efficacy and
safety have been explored in controlled clinical trials
(Smith et al. 1990; Claghorn and Lesem 1995; Marttila
et al. 1995; Richou et al. 1995; Van Moffaert et al. 1995;
Zivkov and De Jong 1995). In all trials tolerance and
safety of mirtazapine were satisfactory. In out-patients
efficacy of mirtazapine was reported to be significantly
superior to placebo (Smith et al. 1990; Claghorn and
Lesem 1995) and to trazodon (Van Moffaert et al.
1995); no significant differences between mirtazapine
and amitriptyline (Smith et al. 1990; Zivkov and De
Jong 1995), clomipramine (Richou et al. 1995) and dox-
epin (Marttila et al. 1995), respectively, have been
found.
Some authors have expressed doubt whether efficacy
of the “newer” antidepressants equals the efficacy of
“older” antidepressants (DUAG 1986; Bech 1988;
Potter and Rudorfer 1989; DUAG 1990), in spite of
the fact that most clinical trials show no differences in
efficacy. The methodology of such trials may not always
be suitable to detect differences. Possible confounding
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factors involved include (Angst et al. 1989; DUAG
1990):
1. High placebo response rates in trials without a pla-
cebo control group;
2. “Unblinding” due to different side-effect profiles;
3. Treatment with suboptimal doses of the reference
drug;
4. Non-compliance and drop-out, especially if not
equally distributed over the different treatment groups;
5. High error variance in multicentre trials;
6. Concomitant treatment with other psychotropic
drugs.
We have performed a study designed to avoid these
methodological problems. The present study, compar-
ing mirtazapine with imipramine, included:
1. A drug-free and a placebo wash-out period of 7
days, to exclude early placebo-responders;
2. Dose adjustment to a fixed blood-level to avoid sub-
optimal dosing of imipramine;
3. Allowing no concomitant psychotropic medication
except in case of intolerable anxiety or intolerable psy-
chotic symptoms;
4. No monitoring of side-effects by the investigators
to avoid unblinding;
5. Inclusion of in-patients only;
6. Single centre design.
Materials and methods
General outline (Fig. 1)
Patients on the in-patient Depression Unit of the Department of
Psychiatry of the University Hospital Rotterdam “Dijkzigt” were
enrolled into the study from December 1989 to December 1993.
This Unit has a regional function for treatment of uncomplicated
depressed patients and a supraregional function for treatment of
therapy-resistant depressed patients. Routinely psychotropic drugs
are discontinued after admission. Depressed patients were screened
for inclusion and exclusion criteria. Eligible patients had to be drug
free for at least 3 days before baseline assessment. After giving writ-
ten informed consent placebo was administered single blind for 4
days. At the end of this period patients were again assessed on the
Hamilton Rating Scale for Depression (HRSD; Hamilton 1960) and
those still meeting inclusion criteria (HRSD ≥ 18) were randomly
allocated to a double-blind treatment with either imipramine or
mirtazapine. Doses of both drugs were adjusted to obtain fixed
blood levels. Outcome was assessed 4 weeks after attaining these
predefined blood levels.
Patient selection
Patients were examined for inclusion and exclusion criteria before
the initial placebo period and the HRSD was administered again
at the end of this period. Included were patients aged 18–65 with a
“major depressive episode” according to a checklist with the DSM-
III-R criteria (APA 1987) and an HRSD score ≥ 18. Excluded were
patients with psychotic depression with hallucinations, schizophre-
nia, paranoid psychosis, organic brain syndrome, chronic drug or
alcohol abuse, clinically relevant renal, hepatic, cardiovascular, or
endocrine disease, presence of absolute contraindication for either
imipramine or mirtazapine, and pregnancy or the risk to become
pregnant.
All assessments were done by one research psychiatrist (JB),
except the SADS (Schedule for Affective Disorders and
Schizophrenia; Spitzer and Endicott 1978/79), which was performed
in the presence of a second psychiatrist. In a clinical interview,
demographic data (age, sex, level of professional training, profes-
sion and marital status), psychiatric history (previous affective dis-
orders, course, duration and treatment of the current episode), and
family history (depression, suicide, alcohol abuse, antisocial behav-
ior, anxiety disorders, drug dependency and other psychiatric dis-
orders) were obtained. The depression part of the SADS was
administered at baseline by one psychiatrist in the presence of a
second psychiatrist to obtain RDC diagnoses (Research Diagnostic
Criteria; Spitzer et al. 1978) and to confirm the DSM-III-R diag-
nosis, obtained using the checklist at inclusion; scoring was based
on consensus between both psychiatrists. To measure severity at
baseline and response during treatment, we performed two depres-
sion rating scales. The HRSD which is internationally the most
widely accepted depression scale was scored at baseline (before and
at the end of the placebo period) and at 2 and 4 weeks after attain-
ing the predefined blood level of study medication. The MADRS
(Montgomery Asberg Depression Rating Scale; Montgomery and
Asberg 1979), which is composed of ten depression symptoms which
have proven to be most sensitive to change during treatment, was
scored at baseline and weekly thereafter.
Study medication
Once a day at 10 p.m. either imipramine or mirtazapine was admin-
istered in identical capsules containing 37.5 or 75 mg imipramine
or 10 or 2 mg mirtazapine, respectively. Treatment was started with
either 75 mg imipramine or 20 mg mirtazapine. After 2 days the
dose was doubled unless severe side effects were observed. Blood
levels were monitored twice a week for the first 2 weeks and weekly
thereafter. The results were send to an independent psychiatrist from
another ward who adjusted the number of capsules on the basis of
these blood levels. The predefined blood level for imipramine +
desmethylimipramine was 200–300 ng/ml (Perry et al. 1987). For
mirtazapine, no therapeutic levels are known. To keep the study
double-blind, to exclude treatment under extremely high or low
blood levels, and to ascertain treatment compliance it was decided
to adjust mirtazapine doses to blood levels around the mean levels
obtained with 60 mg mirtazapine per day. This dosage was advised
at the time the study started by Organon for treatment of depressed
patients. To obtain such levels, we performed a pilot study in 20
patients with a dose of 60 mg. The mean steady-state blood levels
in this pilot study were 67.0 ng/ml (SD ± 25.4, range 33.0–123.9).
On the basis of these results, predefined blood levels of 50–100 g/ml
mirtazapine were chosen. The difference with predefined imipramine
levels is, however, that optimal efficacy is not proven at these
predefined mirtazapine levels.
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Fig. 1 General outline of the study design
Side-effects were not systematically rated by the investigators to
prevent highlighting the different side-effect profiles and thus intro-
ducing a bias towards “unblinding”. Side-effects were observed by
treating psychiatrists and nurses not involved in the ratings for the
study. Only in some drop-out patients was specific treatment for
side-effects necessary according to these observations.
Evaluation of blindness
After completion of the study the research psychiatrist (J.B.) guessed
the medication each of the 107 patients had received. This was cor-
rect in 46 cases and incorrect in 37 cases. In 24 cases the research
psychiatrist was not able to decide on one of the two study med-
ications.
Assay of study medication
Imipramine and desipramine assays were carried out with HPLC.
Mirtazapine was assayed according to the method of Paanakker
and Van Hal (1987).
Concurrent medication
Drugs for somatic complaints not interfering with study medica-
tion were continued unchanged during the study, if necessary. No
psychotropic medication besides the study medication was allowed,
except for 1–6 tablets a day containing 45 mg of an extract of valer-
ian in case of anxiety or insomnia. This extract was assumed to be
without antidepressant effect. In exceptional cases lorazepam,
1–5 mg a day for intolerable agitation or anxiety, or haloperidol,
1–15 mg a day in case of intolerable psychotic symptoms, respec-
tively, had been prescribed.
Data analysis and statistical methods
The main response criterion was defined a priori as a reduction of
50% or more of the HRSD score 4 weeks after attaining the
predefined blood level. The x²-test was used for comparing outcome
scores between the two treatment groups; the t-test for comparing
continuous outcome variables. In order to increase precision of the
estimated treatment effects, ANCOVAs, using multiple linear
regression analyses, were also a priori planned for comparing the
MADRS and HRSD post-treatment scores between the two treat-
ment groups with the following covariables potentially taken into
account: MADRS and HRSD pretreatment scores (baseline sever-
ity), duration of the present episode, number of previous depres-
sions, manic episodes, personality, family history, previous
treatments during current episode, melancholic type, psychotic fea-
tures and type of depression according to RDC criteria. Adequate
pretreatment during the current episode was defined as an adequate
dose of an antidepressant during at least 4 weeks (Potter and
Rudorfer 1989).
The difference in time-trend of the of the MADRS during 6 weeks
of treatment between the two treatment groups was tested in a ran-
dom coefficient model using RM-ANOVA.
Because efficacy of antidepressants may be less in the subgroup
of psychotic patients, separate analysis of this subgroup was planned
a priori.
Ethical considerations
The protocol was approved by the Ethics Committee of the
University Hospital Rotterdam “Dijkzigt” and the Medical
Faculty of the University of Rotterdam and was carried out in
accordance with the ethical standards laid down in the declaration
of Helsinki.
Results
Patient population and drop-outs
One hundred and seven depressed in-patients were ran-
domized to either mirtazapine (n = 54) or imipramine
(n = 53) (Table 1). Eight patients dropped out, while
two patients were excluded from analyses because mon-
itoring of blood levels showed non-compliance (Table
2). Five drop-outs on imipramine were due to side
effects, compared to none on mirtazapine. Thus 97
patients (51 on mirtazapine and 46 on imipramine)
completed the study.
Blood levels and doses
The mean time to reach the predefined blood levels was
10.9 days (SD ± 3.5, range 5–21) for mirtazapine and
13.6 days (SD ± 4.6, range 7–25) for imipramine.
Including the 4-week treatment on this blood level, the
mean total period on study medication was 38.9 days
(SD ± 3.5, range 33–49) for mirtazapine and 41.6 days
(SD ± 4.6, range 35–53) for imipramine. The mean
daily dose during the 4 weeks on the predefined blood
level for mirtazapine was 76.2 mg (SD ± 17.6, range
40–100) with a mean blood level of 69.3 ng/ml (SD ±
10.0, range 48.8–92.8), and for imipramine 235.5 mg
(SD ± 90.8, range 37.5–450) with a mean blood level
of imipramine + desmethylimipramine of 267.1 ng/ml
(SD ± 35.9, range 199.0–400.3). Within this sum, the
mean blood level of imipramine was 119.13 ng/ l (SD
± 44.48, range 44.6–235.0) and the mean desmethylim-
ipramine was 148.01 ng/ l (SD ± 54.6, range
45.0–310.3). 
Concomitant medication
Nine mirtazapine and seven imipramine patients were
treated with the valerian extract. There were no
significant differences between the two treatment
groups with respect to dose and duration of valerian
medication. Lorazepam was administered to six
patients (four on mirtazapine and two on imipramine),
which has been ignored in the analyses because of the
small number of patients (6/107). Nine of the 31 psy-
chotic patients were treated with haloperidol, seven on
mirtazapine and two on imipramine. Only one of those
patients (on mirtazapine) was a responder; the other
eight patients were nonresponders. This indicates, that
haloperidol was not instrumental in the recovery in
those patients.
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Treatment effects
According to the main response criterion 11/51 (21.6%)
patients were responders on mirtazapine and 23/46
(50%) on imipramine; a significant difference (v² =
7.38; df = 1; p = 0.007). In addition, the mean HRSD
score after 4 weeks of predefined blood levels (Table
3) of the imipramine group was significantly lower than
that of the mirtazapine group (mean difference = 5.1;
SE = 1.8; t = 2.83; df = 95; p = 0.006). “Intent to treat’’
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Treatment Reason Day of study med. Day after attaining
predefined blood
level
Mirtazapine 1. Transfer to other ward 14 –
2. Refuse to take medication 12 –
3. Non-compliance (plasma level ↓ ) 31 14
Imipramine 4. Mania 18 4
5. Orthostasis 9 –
6. Deterioration 19 2
7. Fever and delirium 12 2
8. Allergic reaction 21 7
9. Allergic reaction 36 22
10. Non-compliance (plasma level ↓ ) 28 7
Table 2 Drop-outs and non-
completers by non-compliance
(n = 10)
Mirtazepine (n = 54) Imipramine (n = 53)
Age: mean ± SD (range) 45 ± 11 (23–64) 47 ± 10 (27–65)
Sex: male/female 12/42 11/42
Diagnosis : “major depressive episode” 
(DSM-III-R) 54 53
*Unipolar 49 52
Not-psychotic, 1st episode 19 23
Not-psychotic, recurrent 15 14
Psychotic, 1st episode 9 10
Psychotic, recurrent 6 5
*Bipolar 5 1
Not-psychotic 4 1
Psychotic 1 0
Melancholic type 47 45
Major depressive episode (RDC) 54 52
Retarded depression (RDC) 16 16
Agitated depression (RDC) 16 19
Endogenous depression (RDC) 53 50
Suicidal 28 32
HRSD baseline 26.1 ± 4.5 (19–37) 26.5 ± 5.0 (18–37)
MADRS baseline 37.5 ± 6.0 (25–51) 36.2 ± 6.8 (16–54)
Duration current episode
>1 year 34 32
<1 year 20 21
Adequate pretreatment with antidepressants 28 27
Family history (1st /2nd degree)
Depression 28 33
Suicide 10 9
Personality disorder 11 7
Table 1 Total population
(n = 107)
Intention to treat Completers
Mirtazapine Imipramine Mirtazapine Imipramine
(n = 54) (n = 53) (n = 51) (n = 46)
Baseline HRSD 26.1 ± 4.5 26.5 ± 5.0 26.1 ± 4.4 26.7 ± 4.9
Endpoint HRSD 19.6 ± 8.7 15.8 ± 9.6 19.2 ± 8.6 14.1 ± 9.0
Table 3 Mean HRSD-scores
± SD at baseline and endpoint
(after four weeks of predefined
blood level)
analysis (n = 107) with the last HRSD score carried
forward showed 11/54 (20.4%) responders with the
mirtazapine and 23/53 (43.4%) with the imipramine
group (x² = 5.5; df = 1; P = 0.019).
Since nine of the 31 psychotic patients were treated
with haloperidol and since more patients on mirtaza-
pine received haloperidol, we have analysed the results
omitting patients receiving haloperidol. The response
on imipramine, 23/44 (52.3%), differed significantly
from the response on mirtazapine: 10/44 (22.7%)
(v² = 6.7; df = 1; P = 0.008).
Figure 2A (completers) and 2B (ITT with LOCF)
show the mean MADRS scores for the two groups dur-
ing 6 weeks of treatment. According to the RM-
ANOVA, the time-trends were significantly different
between the two treatment groups (completers :
P = 0.003; ITT: P = 0.026). Regression analyses with
severity (HRSD score at baseline), suicidal or psychotic
features (DSM-III-R), duration of current episode, pre-
vious adequate treatment of current episode with
imipramine, with other classical tricyclics or with mod-
ern antidepressants, number of psychiatric admissions
before the current depression, positive family history
for depression and/or suicide, and personality disor-
der as covariables did not improve the precision of the
estimated difference between the two drugs to an appre-
ciable extent.
In the subgroup of 31 psychotic patients four
dropped out (two patients on mirtazapine and two on
imipramine), so 27 psychotic patients completed the
study. According to the main response criterion, 4/14
(28.6%) responded on mirtazapine and 9/13 (69.2%)
on imipramine (v² = 2.98; df = 1; P = 0.084). The mean
HRSD scores after 4 weeks of predefined blood levels
were significantly lower for the imipramine group than
for the mirtazapine group (mean difference = 9.8; SE
= 3.8; t = 2.56; df = 25; P = 0.017). “Intent to treat’’
analysis in the subgroup of 31 psychotic patients
showed 4/16 (25%) responders with the mirtazapine
and 9/15(60%) with the imipramine group (v² = 2.59;
df = 1; P = 0.11). If patients treated with haloperidol
were regarded as drop-outs, an “intent to treat’’ analy-
sis showed the following results : 3/16(18.8%) respon-
ders with the mirtazapine group and 9/15(60%) with
the imipramine group. This is a significant difference
(v² = 3.95; df = 1; P = 0.046). Figure 3A (completers)
and Figure 3B (ITT with LOCF) show the MADRS
scores for the two groups of psychotic patients during
6 weeks of treatment. According to the RM-ANOVA
the time trends were significantly different between the
two treatment groups (completers : P = 0.001; ITT:
P = 0.019).
The overall response rate to treatment was rather
low (50% on imipramine and 22% on mirtazapine).
For this reason we performed subgroup analyses. Ex-
cluding patients with a duration of the depression lon-
ger than 1 year, the response rate on imipramine was
63.3% (19/30) and 31.3% (10/32) on mirtazapine. Ex-
cluding in this subgroup also patients with adequate pre
treatment of the current episode, response rates were
even higher: 69.6% (16/23) on imipramine and 37.5%
(9/24) on mirtazapine. These differences between the
imipramine, and mirtazapine group are not significant,
most likely because of the low number of patients.
Discussion
The most obvious result in this study is the consid-
erable difference in antidepressant efficacy between
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Fig. 2A, B Mean total scores on the Montgomery-Asberg de-
pression rating scale. A Completers (n = 97); B all patients
(n = 107, LOCF)
Fig. 3A, B Mean total score on the Montgomery-Asberg depres-
sion rating scale of the psychotic patients. A Completers (n = 27);
B all psychotic patients (n = 31, LOCF)
mirtazapine and imipramine. Such a difference has not
been reported in previous studies (Smith et al. 1990;
Claghorn and Lesem 1995; Marttila et al. 1995; Richou
et al. 1995; Van Moffaert et al. 1995; Zivkov and De
Jong 1995). A possible explanation may be found in
differences between the present and other trials with
mirtazapine.
Previous studies on mirtazapine (Smith et al. 1990;
Claghorn and Lesem 1995; Marttila et al. 1995; Richou
et al. 1995; Van Moffaert et al. 1995; Zivkov and De
Jong 1995) used a flexible dose design. This may lead
to inappropriate dosing especially with tricyclic anti-
depressants because side effects preventing dose incre-
ments may occur at subtherapeutic doses/blood levels
(Dawling 1982; DUAG 1990). In at least two previous
studies (Smith et al. 1990; Richou et al. 1995) the mean
dose of the tricyclic reference drug was rather low;
111 mg amitriptyline and 113.7 mg clomipramine,
respectively. In the present patient group the mean daily
dose of imipramine was 235.5 mg with a very wide
range (37.5–450 mg). No fewer than nine (20%)
patients were on a dose of 112.5 mg or less, and 17
(37%) patients received 300 mg imipramine per day or
more. This illustrates the range of doses necessary to
obtain therapeutic blood levels. It is not very likely that
such doses would have been administered without
blood level control. With mirtazapine it was not pos-
sible to predefine an optimal blood level because ther-
apeutic blood levels of mirtazapine are not available.
The mean mirtazapine dose of 76 mg/day was above
the dose used in other studies: 53 mg/day (Zivkov and
De Jong 1995) and 47 mg/day (Richou et al. 1995) in
other in-patient studies. The predefined blood level of
mirtazapine was based on steady-state blood levels of
patients on 60 mg/day of mirtazapine, which was the
recommended dose in the previous in-patient mirtaza-
pine studies (Richou et al. 1995; Van Moffaert et al.
1995; Zivkov and De Jong 1995).
It cannot be excluded that mirtazapine has a curvi-
linear blood level response curve, as is the case with
nortriptyline (Perry et al. 1987), and that the present
dose was less effective for that reason. Dose finding or
blood level response studies to clarify this point are not
available. Thus, the imipramine dose in the present
study was in the therapeutic range for all patients, but
this is not certain for all patients on mirtazapine, which
could be one explanation for the difference in efficacy
between both drugs in this study.
In the present study only a minority of patients was
treated with comedication, and the difference in efficacy
between imipramine and mirtazapine remained
significant if these patients were excluded. In the ear-
lier mirtazapine studies (Smith et al. 1990; Claghorn
and Lesem 1995; Marttila et al. 1995; Richou et al.
1995; Van Moffaert et al. 1995; Zivkov and de Jong
1995), short acting benzodiazepines were allowed for
the first 2 weeks and chloral hydrate (0.5–3 g) during
the entire study. It was not reported whether the comed-
ication was equally divided between the two treatment
groups. Angst (1993) has argued that comedication
with benzodiazepines increases response to placebo
treatment and decreases the power of a comparative
trial considerably. It may be of significance, therefore,
that other studies with mirtazapine reported response
percentages as high as 72% (Zivkov and de Jong 1995),
80% (Richou et al. 1995), and 78% (Van Moffaert
et al. 1995), respectively.
The drop-out rate in the present study was low: 9.1%
versus 17–35% in other mirtazapine studies (Smith
et al. 1990; Claghorn and Lesem 1995; Marttila et al.
1995; Richou et al. 1995; Van Moffaert et al. 1995;
Zivkov and De Jong 1995). A high drop-out rate may
bias results of clinical trials even if analyses are based
on “intent to treat” samples (Angst et al. 1989).
Patient selection may also play an important role in
treatment outcome (Ansseau 1992). Similar to the pre-
sent trial, three trials of mirtazapine were performed
with in-patients, comparing it with amitriptyline,
clomipramine, and trazodone, respectively (Richou 
et al. 1995; Van Moffaert et al. 1995; Zivkov and De
Jong 1995). However, other selection criteria differed.
Patients with active suicidal tendencies were excluded
(Smith et al. 1990; Claghorn and Lesem 1995; Marttila
et al. 1995; Richou et al. 1995; Van Moffaert et al. 1995;
Zivkov and de Jong 1995). It is not clear whether
patients with psychotic depressions and patients with
a “melancholic type’’-depression had been included in
these studies. In the present study 29% (31/107) of the
patients had psychotic depressions and 86% (92/107)
fulfilled criteria for melancholic type, respectively. 
Out-patients (Smith et al. 1990; Claghorn and Lesem
1995) or in- and out-patients (Marttila et al. 1995) were
studied in some trials, while in the three trials with in-
patients (Richou et al. 1995; Van Moffaert et al. 1995;
Zivkov and De Jong 1995) those with a duration of the
depression longer than 6 months were excluded. In
three studies (Marttila et al. 1995; Richou et al. 1995;
Van Moffaert et al. 1995) none of the patients had been
treated with an adequate dose of an antidepressant in
the month preceding the trial.
The present results are in some respects comparable
to those of the DUAG studies (DUAG 1986, 1990), in
which the serotonine reuptake inhibitors citalopram
and paroxetine, respectively, were compared with
clomipramine. Differences in favour of clomipramine
were reported in both studies. The authors suggested
that this may be related to inclusion of only in-patients,
rigid adherence to a fixed dose schedule and control of
drug compliance by blood level monitoring. 
The sub-group of psychotic patients showed an even
larger superiority of imipramine over mirtazapine,
response percentages being around 60–70% for
imipramine and around 20–30% for mirtazapine,
depending on the analysis performed. Most of these
results were significant, even with the small number of
psychotic patients studied. Seven patients treated with
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haloperidol were on mirtazapine and only two on
imipramine, also hinting at a better efficacy of
imipramine.Thus the inclusion of psychotic patients
may have contributed to the superiority of imipramine.
The response rate in this study was relatively low;
50% on imipramine compared to 70–80% in other
studies (Potter and Rudorfer 1989). This is probably
due, at least in part, to a lower response rate of patients
with a current depressive episode of long duration and
of patients that had been pretreated with antidepres-
sants, since with the exclusion of these patients, the
response rate was 70% (16/23) on imipramine.
In conclusion, the present study shows a consider-
able difference in antidepressant efficacy between the
new antidepressant mirtazapine and imipramine.
Optimization of treatment with the reference drug
imipramine through blood level control, exclusion of
non-compliance for both drugs, exclusion of most con-
comitant medication and a very low drop-out rate may
have contributed to this result. Also, the selection of
severely ill in-patients, including those with suicidal or
psychotic features, may be significant in this respect,
although it is difficult to ascertain differences between
patient characteristics in different studies. In the patient
population studied imipramine is superior in efficacy
to mirtazapine.
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